<DOC>
	<DOCNO>NCT01243073</DOCNO>
	<brief_summary>This phase II open-label study single agent imetelstat patient essential thrombocytopenia polycythemia vera fail intolerant least one prior therapy , refuse standard therapy .</brief_summary>
	<brief_title>Open Label Study Evaluate Activity Imetelstat Patients With Essential Thrombocythemia Polycythemia Vera</brief_title>
	<detailed_description>For patient ET : To obtain preliminary estimate efficacy imetelstat , measure best hematologic response within first year therapy patient ET fail intolerant least one prior therapy , refuse standard therapy . For patient PV : To obtain preliminary estimate efficacy imetelstat , measure maintenance Hct &lt; 45 % men &lt; 42 % woman ( pre-specified Hct count tolerable ) without phlebotomy myelosuppressive therapy within first year therapy patient PV fail intolerant least one prior therapy , refuse standard therapy .</detailed_description>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>ETSpecific Criteria Confirmed diagnosis ET WHO criteria Patients ET require cytoreduction fail intolerant least one prior therapy , refuse standard therapy Laboratory criterion ( within 14 day first study drug administration ) : Platelets &gt; 600,000/μL ANC ≥ 1500/μL Hemoglobin ≥ 10 g/dL PVSpecific Criteria Confirmed diagnosis PV WHO criteria Patients PV require cytoreduction phlebotomy and/or myelosuppressive agent Patients may fail intolerant least one prior therapy , refuse standard therapy For patient receive phlebotomy , frequency past year must least one phlebotomy every 3 month . Undergone phlebotomy attain Hct &lt; 47 % ( men ) &lt; 45 % ( woman ) ( prespecified Hct count tolerable ) within 14 day prior start study treatment Cessation myelosuppressive agent prior initiation study treatment ( unless approve Geron Medical Monitor unusual circumstance ) Hydroxyurea anagrelide : Cessation 1 day prior initiation study treatment . Consideration time cessation therapy prior start study treatment take account requirement phlebotomy . INFα pegylated INFα : Cessation 4 week prior initiation study treatment Laboratory criterion ( within 14 day first study drug administration ) : Platelets &gt; low limit normal ( LLN ) ANC ≥ 1500/μL General Criteria ( All Patients ) Willing able sign inform consent Male female , age 18 year old ECOG performance status 02 Laboratory criterion ( within 14 day first study drug administration ) : INR ( PT ) aPTT &lt; 1.5 x upper limit normal ( ULN ) Serum creatinine ≤ 2 mg/dL Serum bilirubin &lt; 2.0 mg/dL ( patient Gilbert 's syndrome : serum bilirubin &lt; 3 x ULN ) AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 x ULN Alkaline phosphatase &lt; 2.5 x ULN Any clinically significant toxicity previous cancer treatment and/or major surgery must recover Grade 01 prior initiation study treatment Women childbearing potential must negative pregnancy test agree use effective birth control least 12 week last study treatment imetelstat Male patient must agree use effective birth control partner 12 week last study treatment imetelstat . Exclusion Criteria Patients meet follow criterion exclude screen study entry : Women pregnant breast feed Prior stem cell transplantation Investigational therapy within 4 week prior first study drug administration Clinically significant cardiovascular disease condition include : Uncontrolled congestive heart failure ( CHF ) Need antiarrhythmic therapy ventricular arrhythmia Clinically significant severe conduction disturbance per Investigator 's discretion Ongoing angina pectoris require therapy New York Heart Association ( NYHA ) Class II , III , IV cardiovascular disease ( see Appendix E ) Known positive serology human immunodeficiency virus ( HIV ) Serious comorbid medical condition , include active chronically recurrent bleeding , clinically relevant active infection , cirrhosis , chronic obstructive chronic restrictive pulmonary disease per Investigator 's discretion Any severe , acute , chronic medical psychiatric condition , laboratory abnormality , difficulty comply protocol requirement may increase risk associate study participation study drug administration may interfere interpretation study result , judgment Investigator , would make patient inappropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>imetelstat</keyword>
	<keyword>imetelstat sodium</keyword>
	<keyword>GRN163L</keyword>
	<keyword>telomerase inhibitor</keyword>
	<keyword>telomerase</keyword>
	<keyword>essential thrombocytosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>ET</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>PV</keyword>
</DOC>